Hochschulschrift
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
- Weitere Titel
-
Über die Nutzung der fehlerhaften DNA-Reparatur BRCA1 defizienter Pankreaskarzinomzellen in der medikamentösen Therapie
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Kiel, Christian-Albrechts-Universität, Diss., 2012
- Schlagwort
-
Medizin und Gesundheit
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Kiel
- (wer)
-
Universitätsbibliothek Kiel
- (wann)
-
2012
- Urheber
- URN
-
urn:nbn:de:gbv:8-diss-92650
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Hirsch, Georg Steffen
- Universitätsbibliothek Kiel
Entstanden
- 2012
Ähnliche Objekte (12)
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Biodegradable materials for bone defect repair
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
Material‐Assisted Strategies for Osteochondral Defect Repair
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
HIPK2 regulates DNA double-strand break repair by interaction with BRCA1
Long-term results following atrioventricular septal defect repair
Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Biodegradable materials for bone defect repair
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
Material‐Assisted Strategies for Osteochondral Defect Repair
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
HIPK2 regulates DNA double-strand break repair by interaction with BRCA1
Long-term results following atrioventricular septal defect repair
Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms
FANCJ promotes PARP1 activity during DNA replication that is essential in BRCA1 deficient cells
Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression
Biodegradable materials for bone defect repair
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
Material‐Assisted Strategies for Osteochondral Defect Repair
Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
HIPK2 regulates DNA double-strand break repair by interaction with BRCA1
Long-term results following atrioventricular septal defect repair
Exploiting Synthetic lethality between Germline BRCA1 haploinsufficiency and PARP inhibition in JAK2V617F-positive myeloproliferative neoplasms